Business Wire

Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine

Share

Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated HIPRA for marketing authorization by the European Medicines Agency (EMA) and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age. BIMERVAX® is the first bivalent recombinant protein vaccine against the virus to be authorized in the European Union and the first human health vaccine to be designed and developed in Spain.

HIPRA worked tirelessly to support the development of a technologically agile platform, allowing for the inclusion of more than one variant in a single active substance, previously not achievable in the designs of other vaccines approved in the European Union. Veristat’s global teams collaborated closely with HIPRA to establish a comprehensive strategy to demonstrate the benefits of the next-generation COVID-19 vaccine in adult populations. HIPRA engaged Veristat across clinical studies, encompassing the planning and implementation of the pertinent scientific, operational, and biometrics aspects of the clinical trials.

“Clinical trial activity remains steady in new vaccine development, as COVID-19 continues to impart tremendous health and societal impact on our world,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Maintaining vaccine options for all populations, especially immunocompromised populations, remains vitally important. Congratulations to the entire HIPRA team for putting your tremendous talents and technologies to work in helping to safeguard society further from the often devastating consequences of COVID-19. You have set a new standard for what it means to be a true partner. Veristat is proud to have used our bold thinking and scientific expertise to support HIPRA in the clinical trials for BIMERVAX®.”

Around the globe, health authorities, governments, and biopharmaceutical companies continue their efforts to fast-track the development of therapies or platforms to prevent, diagnose, and treat widespread illness due to COVID-19 and its variants. Veristat’s expertise comes from planning or conducting more than 70 COVID-19 projects for a broad range of therapies, including anti-inflammatories, antivirals, antiseptics sprays, cannabinoids, advanced therapies, probiotics, monoclonal antibodies, and vaccines.

“We are thrilled with the results of the studies completed for BIMERVAX® and we are confident that it will play an important role in vaccination plans,” stated HIPRA. "We would extend our heartiest thank you to the entire Veristat team who has worked so diligently. HIPRA is gratified to know that the efforts and commitment of the teams have resulted in an approved vaccine to advance protection against the virus.”

About Veristat
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. With more than 28 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any program’s clinical, regulatory, statistical, data, or operational challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving patients’ lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release

Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com

The Podium Welcomes the Conquerors of 2023 Taklimakan Rally!2.6.2023 04:33:00 EEST | Press release

Among the 97 autos and 37 motorcycles who have started the Rally in Aksu on May 20, 76 autos and 31 motos have successfully withstood the tough challenges and reached the finish line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005748/en/ As the 15th edition of Taklimakan Rally, the 2023 Taklimakan Rally lasts for 13 days. The 4258 km total stage contains 1 SSS, 9 stages and 2 rest days. The rally sets foot in the south west of Xinjiang and covers 3 regions of Aksu, Kashgar and Hotan. The multi-terrain stages together with the beautiful scenery has attracted 231 competitors from China and abroad to participate. In the auto category, the final victory goes to Zi Yungang/Wang Zengrong from Shanxi Yunxiang Team. Team BAIC contributes to the podium with Zhang Guoyu/Oriol Mena Valdearcos and Liu Yangui/Chen Feng listed the 2nd and 3rd place. As to the moto, Bradley John Cox and Arunas Gelazninkas continued their good per

UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release

More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom